Winton Group LTD Viking Therapeutics, Inc. Transaction History

Winton Group LTD

$2.35 Billion
Q3 2025

A detailed history of Winton Group LTD transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Winton Group LTD holds 68,700 shares of VKTX stock, worth $2.73 Million. This represents 0.07% of its overall portfolio holdings.

Number of Shares

68,700

Holding current value

$2.73 Million

% of portfolio

0.07%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	$23.09 - $42.09 $1.59 Million - $2.89 Million	68,700 New	68,700 $1.75 Million
Q4 2021 Feb 10, 2022	SELL	$4.6 - $6.72 $179,064 - $261,589	-38,927 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$5.58 - $7.04 $133,423 - $168,333	-23,911 Reduced 38.05%	38,927 $244,000
Q2 2021 Aug 10, 2021	SELL	$5.19 - $6.73 $27,652 - $35,857	-5,328 Reduced 7.82%	62,838 $376,000
Q1 2021 Jul 21, 2021	SELL	$5.74 - $9.67 $89,285 - $150,416	-15,555 Reduced 18.58%	68,166 $431,000

Q4 2020 Feb 12, 2021	SELL	$5.3 - $6.71 $822,247 - $1.04 Million	-155,141 Reduced 64.95%	83,721 $471,000
Q3 2020 Oct 30, 2020	SELL	$5.73 - $8.11 $683,239 - $967,028	-119,239 Reduced 33.3%	238,862 $1.39 Million
Q2 2020 Aug 05, 2020	BUY	$4.35 - $8.08 $392,261 - $728,614	90,175 Added 33.66%	358,101 $2.58 Million
Q1 2020 May 11, 2020	SELL	$3.45 - $7.95 $433,834 - $999,704	-125,749 Reduced 31.94%	267,926 $1.25 Million
Q4 2019 Feb 13, 2020	BUY	$6.38 - $8.73 $2.51 Million - $3.44 Million	393,675 New	393,675 $3.16 Million
Q2 2019 Jul 08, 2019	SELL	$7.67 - $10.63 $162,005 - $224,526	-21,122 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$7.58 - $9.94 $160,104 - $209,952	21,122 New	21,122 $210,000

Others Institutions Holding VKTX

# of Institutions

434

Shares Held

66.6M

Call Options Held

7.21M

Put Options Held

3.87M

View Full List

About Viking Therapeutics, Inc.

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

More about VKTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Winton Group LTD with notifications on news.

Account